Tyra Biosciences, Inc.

Tyra Biosciences, Inc.

TYRA·NASDAQ

$26.60

-7.3%
HealthcareBiotechnology

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.

At a Glance

Live Snapshot
Market Cap$1.58B
EPS-2.0100
P/E Ratio-13.23
Earnings Date08/06/2026

tyra

Accumulated Other Comprehensive Income (Loss)

Last Annual Value

393.00K

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

Tyra Biosciences, Inc.

Tyra Biosciences, Inc. Competitors Analysis of Accumulated Other Comprehensive Income (Loss)

TYRA · NASDAQ
CompanyAccumulated Other Comprehensive Income (Loss)
CAGR 3Y
CAGR 5Y
CAGR 10Y
393.00K
1.0%N/AN/A 
SVRA logo
Savara Inc.
NASDAQ:SVRA
-87.00K
N/AN/AN/A
PROK logo
ProKidney Corp.
NASDAQ:PROK
56.00K
-24.5%N/AN/A
1.02M
N/AN/AN/A
82.00K
N/AN/AN/A
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
-7.00K
N/AN/AN/A
524.00K
N/AN/AN/A
961.00K
3.6%2.7%1.2%
269.00K
13.3%N/AN/A
65.00K
93.3%N/AN/A
Tyra Biosciences, Inc.

Tyra Biosciences, Inc. Fair Value Envelope

TYRA · NASDAQ

Our analysis suggests that TYRA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $26.6, this represents a potential HIDDEN relative to our calculated worth for Tyra Biosciences, Inc..

Intrinsic Value
Current Price: $26.6